CTOs on the Move

Alamar Biosciences

www.alamarbio.com

 
Alamar Biosciences is a biotechnology company that has developed a next generation proteomic platform with ultra high sensitivity and multiplexing capability for plasma protein detection and liquid biopsies.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

LifeSpan Biosciences

LifeSpan Biosciences is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

R-Research

R-Research is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Proventys

Proventys, Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetica Bio

Synthetica Bio is a privately held healthcare technology company based in Laguna Beach, California that is developing the next generation of safe and secure generative artificial intelligence (GenAI) solutions for the biopharma industry. The Synthetica Bio platform leverages and optimizes multiple large language models (LLMs) and vector databases to ingest real-time data streams and make actionable knowledge directly available to biopharma discovery, clinical, and commercial teams. The platform enables healthcare professionals to rapidly leverage the power of GenAI within compliance of data security standards required by the industry.

Affinivax

Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine. Affinivax designs each of its vaccine candidates to optimize the protective immune response to one or both of these antigens utilizing the distinctive plug-and-play nature of its proprietary MAPS™ technology platform, presenting the potential opportunity to make a significant step forward in addressing major healthcare challenges posed by novel and resistant infectious diseases. Affinivax was founded in 2014 with a seed investment from the Bill & Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Children`s Hospital.